Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …

Currently, limited information is available to clinicians regarding the long-term efficacy of
omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically …

Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and
long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients with …

Summary Background Omalizumab (Xolair) dosing in severe allergic asthma is based on
serum IgE and bodyweight. In Australia, patients eligible for omalizumab but exceeding …

Background Omalizumab has demonstrated efficacy in clinical trials of patients with asthma,
but real-world data are needed. Objective To assess outcomes after omalizumab initiation in …

BACKGROUND: Omalizumab is a monoclonal antibody indicated for treatment of severe
persistent allergic asthma inadequately controlled despite optimal controller therapy. We …

Background: Inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) are
recommended in patients with asthma that is not well-controlled; however, many patients …

Background Data on the prevalence of perennial versus seasonal allergic asthma in Italy
are lacking; moreover, there is limited evidence on the effect of omalizumab on patient …

Asthma causes a substantial burden of morbidity and mortality, affecting 300 million people
worldwide—a figure predicted to increase to 400 million by 2025. Despite the availability of …

IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …